On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — the regulatory mechanism governing which active pharmaceutical ingredients large-scale compounding "outsourcing facilities" may legally use. The formal notice was published in the Federal Register on May 1, 2026 (91 FR 23431, Docket No. FDA-2018-N-3240), opening a public comment period that closed June 29, 2026.[1] The FDA is now reviewing the submitted comments before issuing a final determination.
The legal mechanism
Under Section 503B of the Federal Food, Drug, and Cosmetic Act, an outsourcing facility may only compound a drug from a bulk drug substance if one of two conditions is met: the substance appears on the 503B Bulks List (meaning FDA has determined there is a documented "clinical need" for compounding it), or the finished compounded drug is on the FDA's drug shortage list at the time of compounding, distribution, and dispensing.[2] Semaglutide and tirzepatide currently satisfy neither condition — the tirzepatide shortage was declared resolved in October 2024 and the semaglutide shortage in February 2025.
What "clinical need" means under the statute
The FDA's determination is specifically a finding of no clinical need — a defined regulatory term, not a general judgment about the drugs' medical value. Per the agency's own framework, the clinical need analysis explicitly does not consider the convenience of a compounded formulation (such as a ready-to-use form) or its cost relative to the FDA-approved product.[2] In other words, the affordability gap between compounded and brand-name GLP-1s — often cited as $150–$300 per month for compounded product versus $1,000-plus for brand-name — is not a factor the statute permits the FDA to weigh in this specific determination.
When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.
What this proposal would and wouldn't change
This specifically targets 503B outsourcing facilities — FDA-registered entities that compound in bulk for distribution to multiple providers or facilities. If finalized, it would formally and permanently close the bulk-compounding pathway for these three substances, even if a future shortage were declared, since a formal "no clinical need" exclusion forecloses the shortage-list workaround as well.
503A pharmacies operate under separate statutory authority and are not directly bound by the 503B Bulks List. However, 503A compounding of an "essentially a copy" product already lost its primary legal basis when the underlying shortage designations were removed in late 2024 and early 2025 — meaning most legal pathways for large-scale compounded GLP-1 access, under either framework, have already substantially narrowed independent of this specific proposal's outcome.
Why the FDA cited safety data alongside the legal determination
The agency's public communications around this proposal referenced more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide as of early 2025, with many involving dosing errors from patients self-administering incorrect doses from multidose vials, some requiring hospitalization.[3] The clinical-need legal test itself does not require a safety finding — the two considerations are legally distinct even though the FDA has presented them together in public messaging.
Litigation context
The Outsourcing Facilities Association, a trade group representing compounding pharmacies, previously challenged the underlying shortage-list removals for both tirzepatide and semaglutide in federal court. Courts denied preliminary injunctions in both cases — a district court ruling on March 5, 2025 let the tirzepatide enforcement deadlines stand — meaning legal challenges to date have not altered the regulatory trajectory that led to this 503B proposal.
What happens next
With the comment period closed, the FDA will review submitted comments before issuing a final rule. There is no statutory deadline requiring a final determination by a specific date. If finalized as proposed, 503B outsourcing facilities — which reportedly produced roughly 30% of U.S. GLP-1 supply at peak compounding volume in 2024 — would be permanently barred from bulk-compounding these three substances.
Compare GLP-1 telehealth providers
Source GLP-1 tracks pricing, licensing, and provider structure across the market.